COLL Collegium Pharmaceutical Inc.

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.

Conference Call Information 

To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q2 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contacts:

Ian Karp

Head of Investor Relations

Danielle Jesse

Director, Investor Relations

                        





EN
24/07/2025

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 11,659 shares at 34.363USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

COLL COLLEGIUM PHARMACEUTICAL INC.
08/12/25 August 12, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 O...

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to...

August 7, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Second Quarter 2025 Financial Results on August 7,...

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q2 2025 Earnings Call.” An audio webc...

July 24, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces $150 Million Share Repurchase Program

Collegium Announces $150 Million Share Repurchase Program STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026. This program replaces a previous $150 million share repurchase program authorized in January 2024 which expired on June 30, 2025, and had $65 million remaining under the progr...

July 7, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET Jefferies Global Healthcare ConferencePresentation: Thursday, June 5, 2025, at 1:25 p.m. ET The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast wi...

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch